rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Precipio, Inc.

PRPO · Nasdaq

Health CareLife-science toolsNot moving yet

PRPO stood above a rising 150-day average in 36 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 14.1% below that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
54% +4 in 4 wk
Insider buys, 12 months
$2,933
Insider sales, 12 months
$201K
Officials’ trades on record
0
Institutions holding
17 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 36 of 52 weeks.

20 Apr – 19 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$187K$0$165KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months3
Buyers · sellers1 · 1
WhoDidSharesTraded
Richard A. SandbergDirectorsold900at $25.0221 May 2026filed 26 May 2026
Richard A. SandbergDirectorsold500at $25.0020 May 2026filed 21 May 2026
Richard A. SandbergDirectorsold2,034at $24.8920 May 2026filed 21 May 2026
Richard A. SandbergDirectorsold600at $24.4219 May 2026filed 21 May 2026
Ahmed Zaki SabetChief Operating Officerbought19at $27.931 Apr 2026filed 10 Apr 2026
Ahmed Zaki SabetChief Operating Officerbought20at $23.402 Jan 2026filed 6 Jan 2026
Ahmed Zaki SabetChief Operating Officerbought20at $23.402 Jan 2026filed 20 Jan 2026
Ahmed Zaki SabetChief Operating Officerbought25at $19.501 Oct 2025filed 20 Jan 2026
Ahmed Zaki SabetChief Operating Officerbought31at $16.308 Jul 2025filed 20 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders17+3 on the quarter
New · exited5 · 2
Reported value$3.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202646,148$1.1M+20,665+81.1%
BlackRock, Inc.added · filed 7 Aug 202634,655$858K+5,633+19.4%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202618,691$463K-120−0.6%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 202616,199$401K-3,101−16.1%
CITADEL ADVISORS LLCreduced · filed 14 Aug 202614,714$364K-402−2.7%
XTX Topco Ltdnew · filed 14 Aug 20269,450$234K+9,450
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 20269,407$233K+62+0.7%
DIMENSIONAL FUND ADVISORS LPnew · filed 11 Aug 20268,396$208K+8,396
UBS Group AGadded · filed 13 Aug 2026343$8,493+116+51.1%
WELLS FARGO & COMPANYunchanged · filed 14 Aug 202650$1,23800.0%
30 Sep 2023 – 30 Jun 2026
101417Sep 23Jun 24Mar 25Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Christina Rizopoulos Valauri Company insiderDirector · last 15 Oct 20260 · 0
David Seth Cohen Company insiderDirector · last 15 Oct 20260 · 4
Jeffrey Cossman Company insiderDirector · last 15 Jul 20260 · 0
Richard A. Sandberg Company insiderDirector · last 21 May 202612 · 7
Ahmed Zaki Sabet Company insiderChief Operating Officer · last 1 Apr 202619 · 0
Kathleen Laporte Company insiderDirector · last 15 Jan 20260 · 1
Ilan Danieli Company insiderChief Executive Officer · last 2 Jan 202614 · 0
Matthew Gage Company insiderChief Financial Officer · last 2 Jan 20260 · 0
Ronald Asbury Andrews Company insiderDirector · last 2 Jan 20260 · 0
Douglas Carl Fisher Company insiderDirector · last 27 Oct 20230 · 0
Carl Iberger Company insiderChief Financial Officer · last 11 Jan 20220 · 0
Mark Rimer Company insiderDirector · last 11 Jan 20220 · 0

Same industry

OABI OmniAbLeading+67%
TXG 10x GenomicsLeading+59%
AVTR AvantorLeading+45%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+35%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202544.5%
Operating profit marginFY 2025 · to 31 Dec 2025-5.0%
Free cash flow marginFY 2025 · to 31 Dec 20251.5%
Return on capital employedFY 2025 · to 31 Dec 2025-6.8%
Debt to equityFY 2025 · to 31 Dec 20250.01×
Research spendFY 2025 · to 31 Dec 20256.7%
Share count trendFY 2025 · to 23 Mar 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.7M
Free cash flowFY 2025 · to 31 Dec 2025$359K

Analyst forecasts

No analyst forecasts yet.